Employees: 529
Size Shanghai Xiao Fang Pharmaceutical (603207.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $503M, the 3685th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥21.04 on 18 Nov 2026.
Performance Over six months the shares fell 17.3%, against -19.6% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 9.8% over the last twelve months (peer median +9.4%); the operating margin is 39.4% (peer median 6.8%).
Valuation It trades at 4.8× enterprise value to sales against a peer median of 3.7× (8th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 34.7 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥554M | CN¥521M | CN¥471M | CN¥472M | CN¥457M |
| Revenue growth | — | +10% | 0% | +3% | — |
| Gross profit | CN¥335M | CN¥337M | CN¥307M | CN¥308M | CN¥268M |
| EBITDA | n/a | CN¥241M | CN¥237M | CN¥233M | CN¥206M |
| Net income | CN¥193M | CN¥207M | CN¥205M | CN¥204M | CN¥175M |
| Free cash flow | CN¥131M | CN¥111M | CN¥128M | CN¥122M | CN¥78.8M |
| Capital expenditure | CN¥71.7M | CN¥54.2M | CN¥83.9M | CN¥80.2M | CN¥61.6M |
| Total debt | CN¥5.55M | CN¥9.65M | CN¥2.32M | CN¥442,274 | CN¥882,770 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603207.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.7% | -2.1% | 9th lowest of 21 |
| 6-month return | -17.3% | -19.6% | 10th highest of 21 |
| Distance from 52-week high | -35.8% | -37.1% | 11th highest of 21 |
| Revenue growth (TTM) | +9.8% | +9.4% | 10th highest of 20 |
| Operating margin | 39.4% | 6.8% | highest of 20 |
| EV / Sales | 4.8× | 3.7× | 8th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | -5.4% | 4.6% | 3rd least demanding of 9 |
| Growth delivered (Del g) | +7.6% | +5.3% | 4th highest of 9 |
| Hurdle (Req g minus delivered) | -13.0 pp | +2.1 pp | 4th least demanding of 9 |
| ROIC minus cost of capital | +34.7 pp | -2.7 pp | highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | 4.8× | -5.4% | +7.6% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | 27.2× | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | 4.0× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | 2.5× | 16.7% | +4.4% |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 71.0× | n/a | n/a |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | 11.0× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | 1.8× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 0.9× | n/a | n/a |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 1.8× | 22.1% | +3.5% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | 2.3× | -6.1% | +9.6% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | 5.6× | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |